ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
221,816
221,816
-91,426
-274,880
-344,681
Depreciation & amortisation
592
592
2,978
3,118
3,663
Stock-based compensation
21,889
21,889
33,888
60,850
55,982
Change in working capital
21,917
21,917
-14,417
1,999
19,331
Accounts receivable
1,479
1,479
-7,141
-2,646
-12,350
Inventory
-3,469
602
231
-269
-1,354
Accounts payable
23,288
23,288
-4,825
13,863
56,411
Other working capital
-27,348
-27,348
-42,036
-173,917
-237,749
Other non-cash items
3,173
3,173
39,114
34,646
26,712
Net cash provided by operating activities
-26,780
-26,780
-41,639
-170,026
-236,613
Cash flows from investing activities
Investments in property, plant and equipment
-568
-568
-397
-3,891
-1,136
Purchases of investments
-552,737
-552,737
-349,457
-330,713
-603,014
Sales/maturities of investments
451,921
451,921
420,580
497,421
415,162
Net cash used for investing activities
261,849
261,849
70,726
162,817
-188,988
Cash flows from financing activities
Debt repayment
-268,408
-268,408
-38,129
-
-
Common stock issued
-
-
0
0
227,260
Common stock repurchased
0
0
-75,825
-
-
Other financing activities
-592
-592
-1,680
-1,994
-2,158
Net cash used provided by (used for) financing activities
-267,316
-267,316
1,118
-693
457,519
Net change in cash
-38,549
-38,549
28,755
-9,126
31,532
Cash at beginning of period
94,409
94,409
65,654
74,780
43,248
Cash at end of period
55,860
55,860
94,409
65,654
74,780
Free cash flow
Operating cash flow
-26,780
-26,780
-41,639
-170,026
-236,613
Capital expenditure
-568
-568
-397
-3,891
-1,136
Free cash flow
-27,348
-27,348
-42,036
-173,917
-237,749